We show that expression of mutant Kras or mutant ERBB2 (ERBB2S310F and ERBB2V777L), two of the most frequent oncogenic drivers in human GBCs, drive rapid tumor development in vivo in the presence of p53 loss. This evidence concerns the gene KRAS and neoplasm.